Skip to content

Evaluation of ArTificial Intelligence System (Gi-Genius) for adenoMa dEtection in Lynch Syndrome.

Evaluation of ArTificial Intelligence System (Gi-Genius) for adenoMa dEtection in Lynch Syndrome. A Randomized, Parallel, Multicenter, Controlled Trial. TIMELY Study.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04909671
Acronym
Timely
Enrollment
404
Registered
2021-06-02
Start date
2021-09-13
Completion date
2023-12-01
Last updated
2022-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lynch Syndrome

Brief summary

The purpose of this study is to assess if artificial intelligence aid colonoscopy colonoscopy is superior to conventional colonoscopy for the detection of adenomas during surveillance colonoscopy in patients with Lynch syndrome.

Detailed description

To compare the performance of white-light colonoscopy (HD-WLE) versus white-light + CAD (CAD) for detection of adenomas (1:1 ratio). The CAD system will include an artificial intelligence-based medical device (GI Genius, Medtronic) trained to process colonoscopy images and superimpose them, in real time, on the endoscopy display as a green box over suspected lesion. An adequate bowel preparation and minimum withdrawal time of 6 min will be required. Colonoscopies will be performed by experienced endoscopists and with high-definition scopes. Lesions will be collected, and histopathology findings used as the reference standard. The primary outcome of this trial will be the mean number of adenomas per colonoscopy (APC).

Interventions

DEVICEGi Genius, Medtronic

GI geniusTM (Medtronic) is an artificial intelligence device designed and validated on a dataset of white-light endoscopy videos from high-quality randomized controlled trials for the detection of colorectal lesions during colonoscopy. Based on a deep learning system using convolutional neural networks, GI genius works in real-time side-to-side with the gastroenterologist during colonoscopy highlighting the presence of precancerous lesions with a visual marker (green box) in real time and designed to be integrated with the majority of colonoscopies.

OTHERWhite light standart colonoscopy

High definition white light endoscopy will be used during the scope withdrawal

Sponsors

European Society of Gastrointestinal Endoscopy
CollaboratorOTHER
Hospital Clinic of Barcelona
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥18 years with a proven pathogenic germline variant in one of the MMR genes (MLH1, MSH2, MSH6) or Epcam deletion who are under surveillance colonoscopy.

Exclusion criteria

* Previous history of total colectomy, * Concomitant inflammatory bowel disease, * Inability or refuse to sign the informed consent, * Previous colonoscopy \< 12 months. * Inadequate bowel preparation. * Incomplete procedure. * PMS2 mutation carriers

Design outcomes

Primary

MeasureTime frameDescription
Mean number of adenomas per colonoscopy18 monthsCompare mean number of adenomas in both arms calculated by dividing the total number of adenomas detected by the total number of colonoscopies in each arm

Secondary

MeasureTime frameDescription
Mean number of polyps per colonoscopy18 monthsCompare mean number of polyps in both arms calculated by dividing the total number of polyps (including serrated lesions and adenomas) detected by the total number of colonoscopies in each arm
Adenoma detection rate18 monthsproportion of individuals undergoing a complete colonoscopy who had at least one adenoma detected between two arms.
Polyp detection rate18 monthsproportion of individuals undergoing a complete colonoscopy who had at least one polyp detected between two arms.
Withdrawal time18 monthstime spent on inspection, from the cecum to endoscope extraction through the anus, excluding the time needed for therapeutic measures (including polypectomy).
Mean number of non-clinically significant removed lesions18 monthsLesions removed and with a histology of normal or inflammatory mucosa or removed diminutive recto-sigmoid polyps with a histology of hyperplastic
Subjective endoscopist measures18 monthsQuestionary addresing the easiness and satisfaction of the procedure, detection of lesions and performance of artificial intelligence will be filled in by each endoscopist
False positives in CAD arm18 monthsCombination of: * Lesions detected by CAD (\>2s green box) after an adequate inspection with a high confidence optical diagnosis negative for neoplasia made by the endoscopist. * Lesions detected by CAD (\>2s green box) after an adequate inspection resected by the endoscopist and with a clinically non-significant histology.

Countries

Spain

Contacts

Primary ContactMaria Pellise, Phd
mpellise@clinic.cat+34 932275400

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026